SCHEMBL25416792

SCHEMBL25416792

CCCc1ccc2c(Br)cnn2c1

nearest known ligand 0.33

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA2 P00918 1/20 0.33
POLB P06746 1/20 0.31
CTDSP1 Q9GZU7 1/20 0.31
MGLL Q99685 1/20 0.31
LPL P06858 2/20 0.31
LIPG Q9Y5X9 2/20 0.31
PLK4 O00444 1/20 0.31
AURKA O14965 1/20 0.31
DYRK3 O43781 1/20 0.31
MAP4K4 O95819 1/20 0.31
NTRK1 P04629 1/20 0.31
INSR P06213 1/20 0.31
CDK1 P06493 1/20 0.31
FGFR1 P11362 1/20 0.31
FLT1 P17948 1/20 0.31
CDK2 P24941 1/20 0.31
MARK3 P27448 1/20 0.31
FLT4 P35916 1/20 0.31
KDR P35968 1/20 0.31
FLT3 P36888 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25417457 0.81 CYP11B1 (0.40) CA2POLB
SCHEMBL25414847 0.75 LTA4H (0.44)
SCHEMBL25416213 0.74 DUT (0.35)
SCHEMBL23089448 0.73 EPHB3 (0.40) PLK4AURKADYRK3MAP4K4NTRK1
SCHEMBL25421596 0.72 PLK4 (0.41) CA2POLBPLK4AURKADYRK3
SCHEMBL19110512 0.70 PRKAB1 (0.63) PLK4AURKADYRK3MAP4K4NTRK1
SCHEMBL25416942 0.70 MAPT (0.37) POLBMAP4K4
SCHEMBL24369877 0.69 EPHB3 (0.42) POLBPLK4AURKADYRK3MAP4K4
SCHEMBL1693666 0.69 MAPK14 (0.38) PLK4AURKADYRK3MAP4K4NTRK1
SCHEMBL31416768 0.69 PRKAB2 (0.47) PLK4AURKADYRK3MAP4K4NTRK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250129067-A1 PLATELET-DERIVED GROWTH FACTOR RECEPTOR (PDGFR) ALPHA INHIBITORS AND USES THEREOF PROGENTOS THERAPEUTICS, INC. (US) 2025-04-24 US disclosed
EP-4430047-A1 PLATELET-DERIVED GROWTH FACTOR RECEPTOR (PDGFR) ALPHA INHIBITORS AND USES THEREOF Progentos Therapeutics, Inc. (US) 2024-09-18 EP disclosed
CN-118475580-A Platelet-derived growth factor receptor (PDGFR) alpha inhibitors and uses thereof 普罗根托斯治疗公司 2024-08-09 CN disclosed
WO-2023081923-A1 PLATELET-DERIVED GROWTH FACTOR RECEPTOR (PDGFR) ALPHA INHIBITORS AND USES THEREOF Frequency Therapeutics, Inc. (US) 2023-05-11 WO disclosed
WO-2023081923-A1 PLATELET-DERIVED GROWTH FACTOR RECEPTOR (PDGFR) ALPHA INHIBITORS AND USES THEREOF Frequency Therapeutics, Inc. (US) 2023-05-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250129067-A1 PLATELET-DERIVED GROWTH FACTOR RECEPTOR (PDGFR) ALPHA INHIBITORS AND USES THEREOF PDGFRB, PDGFRA, PDGFA CA2 4373/4885POLB 2679/4885CTDSP1 2141/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.